Quinz

Quinz has assisted TSG with its acquisition of the Gevitec BV group, consisting of a Belgian-based, founded in 1991 and a Dutch-based company, founded in 2010. Gevitec is specialised in advanced electrical solutions. The TSG Group is the European leader in technical services for responsible mobility solution and a key enabler of the energy transition for mobility. With the acquisition of the Gevitec group, TSG strengthens its presence in Belgium and the Netherlands, especially in the areas of electrical vehicle charging stations and solar segments. The Quinz deal team consisted of Bart Lintermans and Caroline Michiels, who assist the group on an ongoing basis in its buy-and-build strategy.

How does government intervention impact pharmaceutical innovation? On October 24, 2024, Quinz hosted a webinar on this essential topic. Expert panelists from industry, academia, and government shared insights on how the government acts as a facilitator, regulator, and active contributor in driving pharmaceutical innovation. Here are some key takeaways: 🔬 Governmental support and funding is needed to stimulate and de-risk experimental research, opening the door to breakthrough innovations. 🤝 Collaboration between public institutions and private companies is vital for navigating the complexities of regulatory frameworks and translating innovative technologies into practice. 📝 Policy changes can directly influence the speed of bringing innovative drugs and therapies to market, by providing targeted support to innovators, removing regulatory barriers, and creating adaptive legal frameworks to facilitate research and development of emerging technologies. 🔍 Understanding the legal implications of government actions helps companies align their strategies with regulatory compliance. The discussion provided valuable perspectives for professionals in the pharmaceutical, biotech, and healthcare sectors.

🧐Are all members of your group of companies in compliance with competition law? You might want to double check! Recent case law has emphasised that “innocent” group members may be held liable for competition law infringements committed by their fellow group members. This client alert provides an overview of this case law, showing who can be held liable and how to manage this risk. Find out more below 👇

💡 Update on the Belgian enforcement efforts against greenwashing - Flixbus has to remove misleading environmental claims from its Belgian website. After conducting a series of inspections, the Economic Inspection by the FPS Economy found that Flixbus was guilty of several forms of greenwashing on its Belgian website. This included making vague and unsubstantiated claims like "environmentally friendly" and "climate-friendly". Flixbus was first given the chance to voluntarily modify its practices, but did not comply. At the request of the Belgian Economic Inspection, the German Umweltbundesamt initiated legal proceedings. After several appeals, the German Federal Court of Justice ruled definitively against Flixbus on Feb. 20, 2025. More information: https://lnkd.in/eVuzy9iN. To gain further insight into the rules on greenwashing, read our article below. 👇

On International Women’s Day, we want to recognize and celebrate the incredible women on our team. We’re proud to work alongside such brilliant lawyers who bring fresh perspectives, lead with integrity, and inspire those around them. Creating a more inclusive and supportive legal industry is an ongoing effort, and we’re committed to doing our part. To the women of Quinz and beyond—thank you!

🧐Are all members of your group of companies in compliance with competition law? You might want to double check! Recent case law has emphasised that “innocent” group members may be held liable for competition law infringements committed by their fellow group members. This client alert provides an overview of this case law, showing who can be held liable and how to manage this risk. Find out more below 👇

Last week, Stijn De Dier, Joeri Vananroye, and Jasper Van Eetvelde shared their expertise on shareholder exit and exclusion proceedings at the KU Leuven conference on abuse of exit and exclusion mechanisms. 💡Stijn De Dier discussed the subsidiary nature of statutory exit and exclusion claims. Need other remedies be exhausted before such claims can be brought? While subsidiarity is often described strictly, in practice it is applied reasonably. Stijn advocated for a pragmatic approach, in which subsidiarity is not a condition, yet serves as a lens through which the court assesses the facts. 💡Joeri Vananroye focused on liquidity arrangements for shareholders and their creditors within companies and other structures. He cautioned that excessively entrenching a structure in the articles of association or a contract can paradoxically make it more fragile. This issue is particularly prevalent in partnerships used for estate planning. 💡Jasper Van Eetvelde addressed exit at the expense of the company. This novelty in the Belgian Companies and Associations Code (for private limited companies) presents significant opportunities, such as a tailor-made exit option for shareholders. But it also entails risks: ranging from a potential run on the company to the misuse of low-exit shares and challenges in applying distribution tests. A carefully drafted statutory arrangement is advisable. Do you have questions about any of these topics or shareholder conflicts in general? Our dispute resolution team at Quinz is ready to assist you.

Charlotte Reyns on enterprise liability in competition law.

🧐Are all members of your group of companies in compliance with competition law? You might want to double check! Recent case law has emphasised that “innocent” group members may be held liable for competition law infringements committed by their fellow group members. This client alert provides an overview of this case law, showing who can be held liable and how to manage this risk. Find out more below 👇

Today marks Rare Disease Day, a crucial opportunity to raise awareness for the 300 million people worldwide living with a rare disease. On this day, let’s recognize the importance of innovation, collaboration, and policy reform in improving the lives of those affected by rare diseases. Did you know? 🏎️ A new "early and fast access" procedure will be introduced in Belgium starting January 1, 2026. This reform will enhance the current early temporary reimbursement system and add a fast-access procedure, helping patients gain earlier access to innovative treatments by allowing reimbursement of specific medicines prior to marketing authorization. 🔑 Belgium’s Federal Coalition Agreement underscores the government's commitment to improving access to innovative medicines. This includes collaboration with European stakeholders for joint negotiations and purchasing of hard-to-access medications, the creation of a national Clinical Trial Network, the organisation of a Biopharma R&D consultation platform, and the strengthening of IP protection for innovative technologies. 🧪 The EU’s proposed Pharma legislation reform aims to encourage pharmaceutical companies to focus on developing treatments for diseases with no existing therapies. It proposes a modulation of market exclusivity, whereby orphan medicinal products addressing high unmet medicinal needs benefit from the longest market exclusivity, while market exclusivity for well-established use orphan medicinal products, requiring less investment, will be the shortest. It is now up to the EU Member States to discuss if the proposed reform sufficiently incentivises research and development to improve the lives of rare disease patients. Our life sciences team is committed to supporting its clients in bringing innovative treatments to patients as quickly as possible. Our team provides comprehensive support throughout the entire lifecycle, from transactional assistance during R&D and commercial launches to navigating the regulatory landscape in Belgium and the EU.